Advertisement

Retrospective analysis on the management of metastatic gastric cancer patients. A mono-institutional experience. What happens in clinical practice

Abstract

Aims and background. Few studies show what happens outside of randomized clinical trials. The purpose of the study was to describe the clinical management of metastatic gastric cancer patients resident in the Forlì area from 2000 to 2009.
Methods and study design. A total of 270 metastatic gastric cancer patients at diagnosis or relapse were considered. Data from medical records were analysed, and survival probabilities were calculated using the Kaplan-Meier method.
Results. A total of 115 patients received best supportive care, 155 at least one line of chemotherapy, 71 (45.8%) underwent second-line therapy, and 49 (31.6%) required a drug dose reduction during the first cycle of first-line therapy. Twelve (7.7%) patients died within 15 days of finishing the last chemotherapy. Median overall survival with best supportive care or chemotherapy was 3 months (95% CI, 2-4) and 11 months (95% CI, 9-12) (P >0.0001), respectively.
Conclusions. Drug dose reductions and delivery of second-line therapy were common. Chemotherapy given towards the end of life was similar to other experiences. Median overall survival was similar to randomized clinical trials.

Tumori 2013; 99(5): 583 - 588

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.1700/1377.15306

Authors

Manlio Monti, Flavia Foca, Andrea Casadei Gardini, Martina Valgiusti, Giovanni Luca Frassineti, Dino Amadori

Article History

This article is available as full text PDF.

Download any of the following attachments:

Authors

  • Monti, Manlio [PubMed] [Google Scholar]
    Department of Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (FC), Italy
  • Foca, Flavia [PubMed] [Google Scholar]
    Unit of Biostatistic and Clinical Trials, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (FC), Italy
  • Gardini, Andrea Casadei [PubMed] [Google Scholar]
    Department of Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (FC), Italy
  • Valgiusti, Martina [PubMed] [Google Scholar]
    Department of Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (FC), Italy
  • Frassineti, Giovanni Luca [PubMed] [Google Scholar]
    Department of Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (FC), Italy
  • Amadori, Dino [PubMed] [Google Scholar]
    Department of Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (FC), Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.